<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962139</url>
  </required_header>
  <id_info>
    <org_study_id>ON101CLCT04</org_study_id>
    <nct_id>NCT04962139</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Phase-III Study to Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oneness Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oneness Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary efficacy endpoint for this study is the proportion of subjects with complete&#xD;
      closure of Target Ulcer during the 20-week Treatment Phase, which is assessed by the blinded&#xD;
      independent evaluator.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2021</start_date>
  <completion_date type="Anticipated">August 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects with complete closure of Target Ulcer</measure>
    <time_frame>20-week Treatment Phase</time_frame>
    <description>The primary efficacy endpoint for this study is the proportion of subjects with complete closure of Target Ulcer during the 20-week Treatment Phase, which is assessed by blinded independent evaluators.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to complete closure of Target Ulcer</measure>
    <time_frame>20-week Treatment Phase</time_frame>
    <description>Time to complete closure of Target Ulcer during the 20-week Treatment Phase, which is assessed by blinded independent evaluators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with Target Ulcer recurrence</measure>
    <time_frame>12-week Follow-Up Phase</time_frame>
    <description>The proportion of patients with Target Ulcer recurrence, during the Follow-Up Phase.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Chronic Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>ON101 Cream plus Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ON101 cream will be applied twice daily for up to 20 weeks to the Target Ulcer. The SOC will include evaluation to ensure adequate blood flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of a moist wound environment via regular dressing changes, and management of infection through oral antibiotics, if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Cream plus Standard of Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle cream will be applied twice daily for up to 20 weeks to the Target Ulcer.&#xD;
The SOC will include evaluation to ensure adequate blood flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of a moist wound environment via regular dressing changes, and management of infection through oral antibiotics, if necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ON101 Cream</intervention_name>
    <description>Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica</description>
    <arm_group_label>ON101 Cream plus Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle Cream</intervention_name>
    <description>ON101 Cream Placebo</description>
    <arm_group_label>Vehicle Cream plus Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects, male or female, aged 18 to 80 years (inclusive) with Type 1 or Type 2&#xD;
             diabetes undergoing therapy for glycemic control using available diabetes drugs&#xD;
             including insulin.&#xD;
&#xD;
          2. Subject has a glycosylated hemoglobin, HbA1c ≦ 12%.&#xD;
&#xD;
          3. Presence of at least one diabetic foot ulcer that meets all of the following criteria:&#xD;
&#xD;
               1. A full-thickness ulcer of UTWCS Grade I-A or II-A&#xD;
&#xD;
               2. Ulcer size (area) is &gt; 2 cm2 and ≤ 20 cm2 (post-debridement at time of&#xD;
                  randomization)&#xD;
&#xD;
               3. Ulcer is located on or below the malleoli&#xD;
&#xD;
               4. Unresponsive to standard ulcer care and present for &gt; 4 weeks (at time of&#xD;
                  randomization)&#xD;
&#xD;
               5. There is a minimum 3 cm margin between the qualifying Target Ulcer and any other&#xD;
                  ulcers on the specified foot, post-debridement)&#xD;
&#xD;
               6. No active infection by clinical inspection defined by IDSA/IWGDF criteria Note:&#xD;
                  If the subject has more than one qualifying diabetic foot ulcer, the most severe&#xD;
                  ulcer is designated Target Ulcer.&#xD;
&#xD;
          4. Subject has adequate vascular perfusion of the affected limb, confirmed by&#xD;
             Ankle-Brachial Index (ABI) &gt; 0.8 and &lt; 1.3, and transcutaneous pressure of oxygen&#xD;
             (TcPO2) &gt; 30 mmHg on at least one lead.&#xD;
&#xD;
          5. Subject, if female of child-bearing potential, has a negative serum pregnancy test at&#xD;
             screening and willing to use 2 medically accepted methods of contraception (e.g.,&#xD;
             barrier contraceptives [female condom, or diaphragm with a spermicidal gel], hormonal&#xD;
             contraceptives [implants, injectables, combination oral contraceptives, transdermal&#xD;
             patches, or contraceptive rings], and intrauterine devices) during the course of the&#xD;
             study (excluding women who are not of childbearing potential and/or who have been&#xD;
             sterilized).&#xD;
&#xD;
          6. Subject is willing to use an off-loading device for the target ulcer on the plantar&#xD;
             while ambulation for the duration of the study.&#xD;
&#xD;
          7. Subject / identified caregiver trained on the study procedures is able and willing to&#xD;
             comply with study procedures and applicable dressing changes.&#xD;
&#xD;
          8. A signed and dated informed consent form has been obtained from the subject.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. In response to standard of care, ulcer size reduction is &gt; 30% during the two-week&#xD;
             run-in Screening Period (between the first Screening Visit/V0 and Baseline/V2).&#xD;
&#xD;
          2. Ulcers with exposed bone or associated with osteomyelitis. Note: The osteomyelitis&#xD;
             should be ruled out by clinical examination (probing of the wound) or X-ray findings&#xD;
             where found necessary by the Investigator.&#xD;
&#xD;
          3. Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement.&#xD;
&#xD;
          4. Body mass index (BMI) &gt; 42 kg/m2&#xD;
&#xD;
          5. Laboratory values at Screening of:&#xD;
&#xD;
               1. Hemoglobin &lt; 10.0 g/dL&#xD;
&#xD;
               2. White Blood Cells (WBC) &lt; 3.0 X 109 cells/L；&gt; 12.0 X 109 cells/L&#xD;
&#xD;
               3. Liver function studies [Total bilirubin, aspartate aminotransferase (AST) and&#xD;
                  alanine transaminase (ALT)] &gt; 3x the upper limit of normal&#xD;
&#xD;
               4. Albumin &lt; 2.5 g/dL&#xD;
&#xD;
               5. Renal function studies [Serum Creatinine and Urea] &gt; 3x the upper limit of normal&#xD;
&#xD;
          6. Presence of any clinically significant medical condition(s) in medical history during&#xD;
             screening period that, in the opinion of the Investigator, could interfere with wound&#xD;
             healing, including but not limited to the following:&#xD;
&#xD;
               1. Acute or unstable Charcot foot&#xD;
&#xD;
               2. Current sepsis&#xD;
&#xD;
               3. Active malignant disease. A subject, who has had a malignant disease in the past,&#xD;
                  was treated and is currently disease-free, may be considered for study entry.&#xD;
&#xD;
               4. Acquired immune deficiency syndrome (AIDS) or HIV positive.&#xD;
&#xD;
          7. Subject is currently receiving (i.e., within 30 days of randomization visit) or&#xD;
             scheduled to receive any of following medication or therapies, could interfere with&#xD;
             wound healing during the course of the study.&#xD;
&#xD;
               1. immunosuppressants (including chronic systemic corticosteroids)&#xD;
&#xD;
               2. cytotoxic chemotherapy&#xD;
&#xD;
               3. cytostatic therapy&#xD;
&#xD;
               4. autoimmune disease therapy&#xD;
&#xD;
               5. dialysis&#xD;
&#xD;
               6. lower limb revascularization surgery (e.g., angioplasty, artery bypass surgery)&#xD;
&#xD;
               7. growth factors&#xD;
&#xD;
               8. hyperbaric oxygen therapy&#xD;
&#xD;
               9. bioengineered tissue or skin substitutes&#xD;
&#xD;
              10. application of topical steroids to the ulcer surface&#xD;
&#xD;
              11. use of any investigational drug(s)&#xD;
&#xD;
          8. Subjects who need to stand continuously for more than 4 hours / day and have&#xD;
             difficulty to comply with the off-loading instruction.&#xD;
&#xD;
          9. A psychiatric condition (e.g., suicidal ideation), current or chronic alcohol or drug&#xD;
             abuse problem, determined from the subject's medical history, which, in the opinion of&#xD;
             the Investigator, may pose a threat to subject compliance.&#xD;
&#xD;
         10. Has any other factor which may, in the opinion of the investigator, compromise&#xD;
             participation and/or follow-up in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyi-Gen Chen</last_name>
    <role>Study Director</role>
    <affiliation>Oneness Biotech Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendy Lin</last_name>
    <phone>+886 2 2703 1098</phone>
    <phone_ext>564</phone_ext>
    <email>Wendy.Lin@onenessbio.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orthopaedic Specialists of North America, PLLC - DBA - OrthoArizona</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lewis Freed</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ILD Research Center - Carlsbad</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dean Vayser</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research, Inc.</name>
      <address>
        <city>Castro Valley</city>
        <state>California</state>
        <zip>94546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Reyzelman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Limb Preservation Platform, Inc.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawn Cazzell</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Foot and Ankle Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felix Sigal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bay Area Foot Care - San Francisco - Shrader</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monara Dini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colorado Foot and Ankle</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacob Fassman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Global Health Research Center, Inc</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilberto Acosta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Phoenix Medical Research LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oscar Barreto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barry University Foot and Ankle Institute</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Snyder</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weil Foot &amp; Ankle Institute</name>
      <address>
        <city>Mount Prospect</city>
        <state>Illinois</state>
        <zip>60056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Fleischer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Foot &amp; Ankle Center Of Illinois</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Sigle</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedar Health Research, LLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leon Brill</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Biopharma Informatic, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenrick Dennis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Futuro Clinical Trials, LLC</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Caporusso</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

